Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $7.20M | $10.7M | $16.1M |
| Revenue growth | — | 48.4% | 50.7% |
| Gross profit | $4.31M | $7.04M | $11.4M |
| Gross margin | 59.9% | 65.9% | 70.8% |
| Operating income | -$28.7M | -$33.1M | -$41.3M |
| Operating margin | -398.0% | -309.6% | -256.3% |
| Net income | -$28.3M | -$27.8M | -$42.6M |
| Net margin | -393.4% | -260.4% | -264.4% |
| EPS (diluted) | $1.34 | $1.12 | $1.41 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$22.6M | -$23.5M | -$38.2M |
| Capital expenditures | — | — | $176K |
| Free cash flow | — | — | -$38.4M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $26.2M | $54.9M | $59.7M |
| Total assets | $44.0M | $70.2M | $77.5M |
| Total liabilities | $12.7M | $9.81M | $11.0M |
| Long-term debt | $5.00M | $2.92M | $4.50M |
| Shareholders' equity | $31.2M | $60.4M | $66.4M |
| Retained earnings | -$217M | -$245M | -$288M |
| Shares (wtd avg diluted) | 21.2M | 24.8M | 30.2M |
Every figure is extracted from Profound Medical Corp.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.